Cymabay Therapeu Stock Cash Per Share
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Cymabay Therapeu fundamentals help investors to digest information that contributes to Cymabay Therapeu's financial success or failures. It also enables traders to predict the movement of Cymabay Stock. The fundamental analysis module provides a way to measure Cymabay Therapeu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cymabay Therapeu stock.
Cymabay |
Cymabay Therapeu Company Cash Per Share Analysis
Cymabay Therapeu's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Cymabay Therapeu Cash Per Share | 1.81 X |
Most of Cymabay Therapeu's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cymabay Therapeu is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Cymabay Therapeu has a Cash Per Share of 1.81 times. This is 58.39% lower than that of the Pharmaceuticals sector and 58.2% lower than that of the Health Care industry. The cash per share for all United States stocks is 63.87% higher than that of the company.
Cymabay Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cymabay Therapeu's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cymabay Therapeu could also be used in its relative valuation, which is a method of valuing Cymabay Therapeu by comparing valuation metrics of similar companies.Cymabay Therapeu is currently under evaluation in cash per share category among its peers.
Cymabay Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X | |||
| Price To Sales | 119.98 X | |||
| Revenue | 31.07 M | |||
| Gross Profit | (41.63 M) | |||
| EBITDA | (101 M) | |||
| Net Income | (105.37 M) | |||
| Cash And Equivalents | 153.42 M | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 114.49 M | |||
| Debt To Equity | 1.45 % | |||
| Current Ratio | 12.20 X | |||
| Book Value Per Share | 2.57 X | |||
| Cash Flow From Operations | (72.53 M) | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (0.99) X | |||
| Target Price | 32.5 | |||
| Number Of Employees | 101 | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.73 B | |||
| Total Asset | 434.69 M | |||
| Retained Earnings | (978.23 M) | |||
| Working Capital | 366.96 M | |||
| Current Asset | 42.79 M | |||
| Current Liabilities | 6.15 M | |||
| Z Score | 16.7 | |||
| Net Asset | 434.69 M |
About Cymabay Therapeu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cymabay Therapeu's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cymabay Therapeu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cymabay Therapeu based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |